arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Lantheus Holdings, Inc.

LNTH
$100.97 ▼ -0.09 (-0.08%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
51 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Lantheus Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.5B
Dividend Yield
Revenue Growth 1.2%
Op. Margin 21.6%
ROIC 5.1%
FCF / Share $1.93
Trailing P/E 55.2x
Price / Book 5.4x
FCF Yield 1.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$377.33M
↑ +1.2%
Net Income Profit after all expenses
$118.42M
↑ +62.3%
Operating Margin Operating profit as % of sales
21.6%
↑ +13.6% 75th
FCF / Share Free cash flow per share
$1.93
↑ +23.4%
Long-Term Debt Long-term obligations
$181.72M
↓ -18.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
80
Returns
88
Financial Health
89
Cash Quality
82

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters